+44 (0)1865 595230
0 Items

Welcome to The Native Antigen Company

World leading infectious disease reagents from the experts. Whether you need cutting edge reagents for your research or bulk products for manufacturing we can support all of your needs.
MXRA8 Receptor

Yellow Fever Donor Sera

We now offer a unique panel of YFV donor sera, from a range of donors immunised with Yellow Fever vaccine. Samples are available from each donor prior to vaccination, and at 2-week and 6-week time points, to allow for assessment of IgM and IgM responses across broad profiles. Our YFV sera is appropriate for use in diagnostic immunoassay controls, for both YFV assays and to investigate assay cross-reactivity with other flaviviruses.

Zika Immunoassay Kit

Zika Total Antibody Immunoassay

Our new ELISA assay is a novel format for detecting serological responses to Zika, with excellent specificity and sensitivity, and an assay time of less than 2 hours. This assay is suitable for measuring Zika responses in any species, making it an ideal choice for animal model studies.

Mammalian-Expressed Proteins

Dengue NS1s, VLPs and Antibodies

The Native Antigen Company offer an extensive range of Dengue virus proteins, prepared in our mammalian cell expression system. Our antigens and antibodies are used by leading IVD and pharmaceutical companies for manufacturing and R&D.

About The Native Antigen Company

The Native Antigen Company (NAC) specialises in the development and manufacture of both native and recombinant antigens, antibodies and immunoassays for viruses and bacteria. Our antigens are used by leading pharmaceutical companies and IVD manufacturers in cutting-edge vaccine research and serology where proper folding and glycosylation are vital. As well as offering antigens from a rapidly expanding portfolio, NAC is increasing its range of highly specific antibodies and ELISA immunoassays. Our expertise is also available to customers on a contract basis for those needing custom protein manufacture in our proprietary mammalian cell protein expression system, together with antibody and immunoassay development.

Antigens

We produce infectious disease antigens from a range of established and emerging viral, bacterial and protozoal pathogens. We provide both native and recombinant antigens, produced using our mammalian expression system. Our antigens are suitable for use in vaccine R&D as components for serological-based diagnostic assays and for fundamental research into infectious diseases. We have a wealth of experience in providing bulk and customised antigen formats for the life sciences industry.

Antibodies

We are developing the world’s most extensive range of antibodies for infectious disease targets. Our portfolio includes a unique panel of highly specific antibodies for flavivirus NS1 proteins, such as serotype-specific reagents for Dengue and human chimeric antibodies to Zika NS1.

Immunoassays

Our immunoassays for Zika virus are the most specific and sensitive assays available on the market. We offer assays for the detection of serological response to infection and to measure levels of Zika NS1 protein during infection.

Contract and Custom services

Our team has decades of experience in the field of native antigen and recombinant protein contract research, process development and production. NAC can undertake custom projects to manufacture proteins and antigens, prepare antibodies and develop immunoassays to suit your R&D needs. Our development laboratories are fully staffed by a team of PhD molecular biologists and development scientists who are able to execute projects as short as a few days through to long-term programmes of a year or more.

Challenges to Effective Yellow Fever Diagnostics

Yellow fever is a haemorrhagic viral disease, transmitted by infected mosquitos in Africa and South America. While an effective vaccine is available, inadequate vaccination of endemic areas has made diagnostics a necessity to controlling ongoing outbreaks. However,...

Five Methods You Can Use to Overcome Zika-Dengue Cross-Reactivity

Cross-reactivity between the Zika and Dengue viruses in serological assays is one of the biggest challenges faced by the epidemiologists, academics and pharmaceutical companies trying to control the Zika epidemic, as it brings the quality and reliability of diagnostic...

Why Zika virus’s cross-reactivity with Dengue might be hampering your research

Given the impact of Zika, it’s no surprise that a global contingent of epidemiologists, academic researchers, and pharmaceutical companies are striving to develop effective disease control measures and treatments. One challenge currently hindering the...

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

10 + 4 =

Live Customer Feedback